| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 01/09/2003 | WO2003002058A2 Bone anabolic compounds and methods of use |
| 01/09/2003 | WO2003001984A2 Method and apparatus for the photomodulation of living cells |
| 01/09/2003 | WO2003001968A2 Compositions and methods for inhibiting platelet activation and thrombosis |
| 01/09/2003 | WO2003001881A2 Cell-based high-throughput screening methods |
| 01/09/2003 | WO2002083674A3 Compositions containing imidazotriazinone for nasal application |
| 01/09/2003 | WO2002074304A3 Composition containing a gallium (iii) complex and a therapeutically effective cytostatic agent |
| 01/09/2003 | WO2002071874A3 Composition improving age-related physiological deficits and increasing longevity |
| 01/09/2003 | WO2002069994A3 Combined use of derivatives of glp-1 analogs and ppar ligands |
| 01/09/2003 | WO2002059558A3 Means and methods for treatment evaluation |
| 01/09/2003 | WO2002059111A3 Pyrazole compounds useful as protein kinase inhibitors |
| 01/09/2003 | WO2002042437A3 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof |
| 01/09/2003 | WO2002036093A3 Anti-adiposis composition based on garlic bulb extracts |
| 01/09/2003 | WO2002032953A3 Pregnancy-associated plasma protein-a2 (papp-a2) |
| 01/09/2003 | WO2002024726A3 Olfactory and pheromones g-protein coupled receptors |
| 01/09/2003 | WO2002015845A3 Anti-hypercholesterolemic drug combination |
| 01/09/2003 | WO2002014485A3 Kallikrein gene |
| 01/09/2003 | WO2002009762A3 Non-peptide ccr1 receptor antagonists in combination with cyclosporin a for the treatment of heart transplant rejection |
| 01/09/2003 | WO2002009716A3 Use of an aldehyde 5-oxo-1,2,4-triazine hydrazide for the treatment of cancer |
| 01/09/2003 | WO2002008407A3 Gene-targeted non-human mammal with human fad presenilin mutation and generational offspring |
| 01/09/2003 | WO2002005850A3 Enhancement of the action of anti-infective agents |
| 01/09/2003 | WO2002000017A3 Erk-5 deficient animals and methods of inhibiting angiogenesis through the inhibition of erk-5 |
| 01/09/2003 | WO2001098351A3 G-protein coupled receptors |
| 01/09/2003 | WO2001098294A3 Vitronectin receptor antagonist pharmaceuticals for use in combination therapy |
| 01/09/2003 | WO2001097793A3 2-arachidonylglycerol (2-ag) - an inhibitor of tumor necrosis factor -alfa and neuroprotector of brain in closed head injury |
| 01/09/2003 | WO2001091740A3 Compositions containing naphthaquinone and an antiproliferative agent |
| 01/09/2003 | WO2001090390A9 Use of baculovirus vectors in gene therapy |
| 01/09/2003 | WO2001070776A3 Nimr compositions and their methods of use |
| 01/09/2003 | WO2001062297A9 Compositions and methods for enhancing drug delivery across biological membranes and tissues |
| 01/09/2003 | WO2001057267A9 Methods and materials relating to cub domain polypeptides and polynucleotides |
| 01/09/2003 | WO2001056532A9 Neuroprotective, antithrombotic and anti-inflammatory uses of activated protein c (apc) |
| 01/09/2003 | WO2001055336A9 Methods and materials relating to cd84-like polypeptides and polynucleotides |
| 01/09/2003 | US20030009777 Using galanin agonist in the generation of medicament for the treatment of nerve damage |
| 01/09/2003 | US20030008924 Providing cell which overexpresses a Bcl-2 family protein; gossypol compound; treating with cell with an effective amount of gossypol compound under conditions such that apoptosis in cell is modulated |
| 01/09/2003 | US20030008923 Administering combination comprising an mTOR inhibitor and an antineoplastic alkylating agent |
| 01/09/2003 | US20030008912 Methods for treating circadian rhythm phase disturbances |
| 01/09/2003 | US20030008910 Use of proteasome inhibitors to treat dry eye disorders |
| 01/09/2003 | US20030008906 Administering benzothiazole compound for therapy, prophylaxis of disease |
| 01/09/2003 | US20030008905 Increasing the capacity of insulin providing cells in an animal by administering to animal a dose of at least one Dipeptidyl-peptidase (DP IV) enzyme activity effector |
| 01/09/2003 | US20030008897 Using compounds such as N,N-dimethyl-1-(1-(4-chlorophenyl)cyclobutyl)-3-methylbutyl amine hydrochloride for therapy of weight gain associated with treatment with certain drug therapy such as the use of tricyclic antidepressants |
| 01/09/2003 | US20030008892 Pharmaceutical composition and method of modulating cholinergic function in a mammal |
| 01/09/2003 | US20030008887 Methods for inhibiting the transmission of HIV using topically applied substituted 6-benzyl-4-oxopyrimidines |
| 01/09/2003 | US20030008875 Use of regularly scheduled high dose intravenous methotrexate therapy, with interim administration of immunomodulatory agents, to treat multiple sclerosis and other diseases of the central nervous system |
| 01/09/2003 | US20030008870 Prophylaxis of painful uterine cramps, dysmenorrhea, in women |
| 01/09/2003 | US20030008869 Combination of a PTPase inhibitor and a sulfonylurea agent |
| 01/09/2003 | US20030008866 Bicyclic inhibitors of glycogen synthase kinase 3 |
| 01/09/2003 | US20030008864 Treatment of diseases involving cyst formation |
| 01/09/2003 | US20030008854 Use of NF-kappabeta inhibitors to treat dry eye disorders |
| 01/09/2003 | US20030008852 Transdermal system containing acetylsalicylic acid for treatment of migraine |
| 01/09/2003 | US20030008847 Treatment of diabetes and related pathologies |
| 01/09/2003 | US20030008846 Use of dopamine receptor antagonists in palliative tumor therapy |
| 01/09/2003 | US20030008844 Administering formulatin comprising iduronylglycosaminoglycan sulfate and dermatan sulfate or their salts, solvates, hydrates or clathartes for therapy and prophylaxis of inflammatory bowel disease |
| 01/09/2003 | US20030008842 Formulations of adenosine a1 agonists |
| 01/09/2003 | US20030008840 Methods for treating cancer |
| 01/09/2003 | US20030008822 Use of IL-18 inhibitors for the treatment or prevention of sepsis |
| 01/09/2003 | US20030008821 Methods of preventing UVB-induced skin damage |
| 01/09/2003 | US20030008818 Compositions containing inclusion complexes |
| 01/09/2003 | US20030008809 Use of 5-HT (3) receptor antagonists for treating musculoeskeletal diseases |
| 01/09/2003 | US20030008807 Novel signaling pathway for the production of inflammatory pain and neuropathy |
| 01/09/2003 | US20030008806 Inhibitors of phosphodiesterases (PDEs) such as papaverine for treatment of drug dependence and psychological disorders |
| 01/09/2003 | US20030008391 Methods and compositions for modulating the interaction between the APJ receptor and the HIV virus |
| 01/09/2003 | US20030008376 Methods and compositions for modulating the interaction between the APJ receptor and the HIV virus |
| 01/09/2003 | US20030008369 Genetic and epigenetic manipulation of ABC transporters and ecto-phosphatases |
| 01/09/2003 | US20030008354 Peptide for use in the diagnosis and treatment of parkinson's, cancer and developmental defects |
| 01/09/2003 | US20030008293 Detection of polymorphism in preferential nucleotide sequences; obtain cells, extract nucleotide sequences, incubate with probe, detect signal, monitor hybridization pattern |
| 01/09/2003 | US20030008284 Polynucleotides related to colon cancer |
| 01/09/2003 | US20030008279 Cells for use in the diagnosis and treatment of viral diseases |
| 01/09/2003 | US20030008273 Methods for increasing the survival of neuronal cells |
| 01/09/2003 | US20030008048 Lipid soluble soft gel cap; hard water soluble capsule shell |
| 01/09/2003 | US20030008021 Complex mixtures exhibiting selective inhibition of cyclooxygenase-2 |
| 01/09/2003 | US20030008020 Sexual disorders; vasodilation |
| 01/09/2003 | US20030008019 Aqueous solution; efficient penetration |
| 01/09/2003 | US20030008018 Acrochordon alleviation |
| 01/09/2003 | US20030008012 Bactericide in solid form |
| 01/09/2003 | US20030008008 Fast dissolving orally consumable films |
| 01/09/2003 | US20030007996 Therapies for the prevention and treatment of diabetes and obesity |
| 01/09/2003 | US20030007988 Slimming cosmetic composition comprising a plant extract containing a plant natriuretic peptide (PNP) |
| 01/09/2003 | US20030007983 Two-hybrid assay that detects HIV-1 reverse transcriptase dimerization |
| 01/09/2003 | US20030007969 Administering integrin antagonist |
| 01/09/2003 | US20030007968 Administering bone marrow cells with lymphyocytes removed; then busulfan |
| 01/09/2003 | US20030007966 Adult respiratory distress syndrome |
| 01/09/2003 | US20030007958 Mixture of silica, flow control agent and carrier; cyclooxygenase inhibitor, antiinflammatory agents |
| 01/09/2003 | US20030007953 Animal food; prevention acidosis |
| 01/09/2003 | US20030007939 Pharmaceutical compositions and methods for managing dermatological conditions |
| 01/09/2003 | US20030007934 Delivery of stimulants through an inhalation route |
| 01/09/2003 | US20030007933 Delivery of muscle relaxants through an inhalation route |
| 01/09/2003 | US20030007932 Drug delivery; overcoated solid dried active solid |
| 01/09/2003 | US20030005927 Process and device for inhalation of particulate medicaments |
| 01/09/2003 | US20030005924 Delivery of beta-blockers through an inhalation route |
| 01/09/2003 | CA2452393A1 Hydrophobic dopamine agonists administered to the dermis |
| 01/09/2003 | CA2452390A1 Use of tyrosine kinase inhibitors for treating bone loss |
| 01/09/2003 | CA2452371A1 Use of tyrosine kinase inhibitors for treating allergic diseases |
| 01/09/2003 | CA2452368A1 New potent, selective and non toxic c-kit inhibitors |
| 01/09/2003 | CA2452361A1 Use of tyrosine kinase inhibitors for treating autoimmune diseases |
| 01/09/2003 | CA2452321A1 Enhanced pharmacokinetic profile of hydrophobic substances |
| 01/09/2003 | CA2452202A1 Diagnostic methods and agents |
| 01/09/2003 | CA2452200A1 Method for identifying compounds that specifically deplete mast cells |
| 01/09/2003 | CA2452196A1 T cell regulatory genes and methods of use thereof |
| 01/09/2003 | CA2452171A1 Use of potent, selective and non toxic c-kit inhibitors for treating mastocytosis |
| 01/09/2003 | CA2452169A1 Use of tyrosine kinase inhibitors for treating inflammatory diseases |
| 01/09/2003 | CA2452167A1 Use of tyrosine kinase inhibitors for treating multiple sclerosis (ms) |